The purpose of this study was to evaluate the cost-effectiveness of olaparib vs. placebo as a maintenance therapy in patients with PSR ovarian cancer with BRCA1/2 mutation from a Chinese healthcare perspective. The gene discussed is BRCA1; the disease is ovarian carcinoma.